 |
 |
 |
|
 |
articles < press << main |
 |
 |
|
|
|
|
|
|
|
| date | | | | title / topic / summary | sort by topic |
|---|
|
| 05/14/2003 | | | | Nymox Reports First Quarter Results
topic: Financial
May 14, 2003: For the three months ending March 31, 2003, Nymox reported a net loss of $928,490, or $0.04 per share, compared to $883,017, or $0.04 per share in the first quarter of 2002. |
| 05/13/2003 | | | | Nymox AlzheimAlert™ Urine Test Useful to Monitor Alzheimer Treatment According to New Studies
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
May 13, 2003: Scientists from Nymox Pharmaceutical Corporation announced today that the Nymox AlzheimAlert™ test helps in the diagnosis of Alzheimer's disease (AD), and shows promise as a tool to monitor progression of the disease. Data from prospective and retrospective double blind controlled independent studies of the AlzheimAlert™ test in AD indicate that the AlzheimAlert™ test values accurately distinguish verified AD patients from controls, suggesting that it may become an important tool for monitoring emerging therapies for AD. |
| 05/01/2003 | | | | Nymox's NicAlert™ Checks for Winners in Quit Smoking Contest
topic: Tobacco Exposure Tests
May 1, 2003: Nymox Pharmaceutical Corporation announced today that the Company's NicAlert™ product has been used in another government-sponsored quit smoking initiative. |
| 04/29/2003 | | | | New Study Supports Statin Drugs Potential in Alzheimer Patients
topic: Statins and Alzheimer's Disease
April 29, 2003: A newly published study has added support to the potential of statin drugs for Alzheimer's disease. Nymox Pharmaceutical Corporation holds a U.S. patent and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. |
| 04/24/2003 | | | | Availability of AD Treatments Increases the Value of Nymox's AlzheimAlert™
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
April 24, 2003: The increased acceptance and availability of treatments for Alzheimer's disease adds to the value of Nymox's AlzheimAlert™ product for physicians, patients and healthcare providers, according to Dr. Michael Munzar, Medical Director of Nymox. |
| 04/23/2003 | | | | Nymox E. Coli Treatment Targets a Pressing Need
topic: R&D: E coli and Other Antibacterial Treatments
April 23, 2003: Nymox Pharmaceutical Corporation has developed NXC-4720, a novel antibacterial product which targets an important pressing need for the public and for the meat industry. Recent studies have shown that treatment with NXC-4720 cleared infected beef of E. coli O157 contamination and helped prevent further E. coli contamination. |
| 04/17/2003 | | | | Nymox Appoints New Senior Manager for Global Sales and Marketing
topic: Appointments
April 17, 2003: Nymox Pharmaceutical Corporation is pleased to announce the appointment of Brian Doyle BSC, MBA as its new Senior Manager for Global Sales and Marketing. |
| 04/16/2003 | | | | Fourth Manhattan Alzheimer's Disease Conference on May 27 Sponsored by Nymox Will Feature World Class Assembly of Speakers and Panelists
topic: R&D: Alzheimer's Disease Treatments
April 16, 2003: Nymox Pharmaceutical Corporation is pleased to announce that it will sponsor the Fourth Manhattan Alzheimer's Disease Conference at the Waldorf Astoria Hotel in New York City on May 27, 2003. Amongst the distinguished speakers there will be world experts on existing drug treatments for Alzheimer's Disease (AD), future drugs for AD, novel approaches to therapy of AD, molecular diagnostics of AD, and molecular biology of AD. |
| 04/15/2003 | | | | Nymox's NicAlert™ Can Detect Second-Hand Smoke Exposure in the Home
topic: Tobacco Exposure Tests
April 15, 2003: Nymox Pharmaceutical Corporation's NicAlert™ product can help parents determine the level of a child's exposure to second-hand smoke at home. The Environmental Protection Agency (EPA) has newly announced the launching of national and local campaigns to urge parents to make their home smoke-free to protect their children's health. |
| 04/10/2003 | | | | Nymox Reports Positive Results for NXC-4720 E. Coli Treatment
topic: R&D: E coli and Other Antibacterial Treatments
April 10, 2003: Nymox Pharmaceutical Corporation announced today positive results for NXC-4720, its treatment for E. coli O157 contamination. NXC-4720 was shown in controlled studies to successfully retard E. coli growth and contamination of meat products. |
|